This fourth major workshop in the series of Pharmacogenomics Workshops that started in 2002, will focus on the implementation and integration of biomarkers and pharmacogenomics from the early to late stage clinical phases of the development of new drugs, biologics and associated devices. An important focus of the workshop will be on ways to facilitate the translation of biomarkers and pharmacogenomics into medical product development and clinical practice.
Recent activities and initiatives, such as the formation of a variety of biomarker-focused consortia, several new regulatory guidance documents, the introduction of legislative bills, and high profile safety concerns continue to illustrate the prominent role biomarkers and pharmacogenomics play, or will play in moving drug development and therapy from a population-based to an individualized paradigm.
Recent activities and initiatives, such as the formation of a variety of biomarker-focused consortia, several new regulatory guidance documents, the introduction of legislative bills, and high profile safety concerns continue to illustrate the prominent role biomarkers and pharmacogenomics play, or will play in moving drug development and therapy from a population-based to an individualized paradigm.
